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Summary
Ferroportin (SLC40A1) is an iron transporter postulated to play roles in intestinal iron absorption and cellular iron release.
Hepcidin, a regulatory peptide, binds to ferroportin and causes it to be internalized and degraded. If ferroportin is the
major cellular iron exporter, ineffective hepcidin function could explain manifestations of human hemochromatosis disor-
ders. To investigate this, we inactivated the murine ferroportin (Fpn) gene globally and selectively. Embryonic lethality of
Fpnnull/null animals indicated that ferroportin is essential early in development. Rescue of embryonic lethality through
selective inactivation of ferroportin in the embryo proper suggested that ferroportin has an important function in the
extraembryonic visceral endoderm. Ferroportin-deficient animals accumulated iron in enterocytes, macrophages, and
hepatocytes, consistent with a key role for ferroportin in those cell types. Intestine-specific inactivation of ferroportin
confirmed that it is critical for intestinal iron absorption. These observations define the major sites of ferroportin activity
and give insight into hemochromatosis.Introduction
Hereditary hemochromatosis is a disorder of iron homeostasis
(Hentze et al., 2004). Homozygous mutations in any of four
genes (HFE, TFR2, hepcidin, and HJV) result in similar pheno-
types of varying severity (Camaschella et al., 2000; Feder et
al., 1996; Papanikolaou et al., 2004; Roetto et al., 2003). Pa-
tients have pathological iron deposition in parenchymal cells
of the liver, heart, pancreas, and other tissues. Paradoxically,
macrophages retain less iron than in normal individuals. Under-
standing the pathogenesis of hemochromatosis requires in-
sight into normal iron homeostasis and its perturbations in
disease.
Mammalian iron homeostasis is maintained through complex
regulation of tissues that transport, store, and utilize iron. Initial
iron stores are established through maternoembryonic and ma-
ternofetal transfer. After birth, dietary iron is absorbed through
enterocytes lining the duodenum. Iron circulates in the blood-
stream bound to transferrin and is delivered to sites of utiliza-
tion and storage. Erythroid precursors are the primary consum-
ers, using iron to produce hemoglobin. Iron is recycled by
tissue macrophages that phagocytose senescent erythrocytes
and disassemble hemoglobin to return the metal to the circula-
tion. Macrophage recycling is quantitatively important because
the amount of iron supplied in this way is approximately 20-
fold greater than the amount absorbed through the intestine on
a daily basis (Hentze et al., 2004). Iron in excess of basal needs
is stored in hepatocytes and macrophages. Unlike other met-
als, iron cannot be eliminated from the body through the liver
or kidneys. Iron losses result from bleeding and exfoliation ofCELL METABOLISM : MARCH 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEskin and mucosal cells. Homeostasis functions to meet tissue
iron needs while averting the toxicity of excess iron.
Iron homeostasis can be described in a simple manner by
considering the actions of six cell types—extraembryonic vis-
ceral endodermal and placental cells that transfer iron from
mother to fetus, absorptive enterocytes, erythroid precursors,
recycling macrophages, and hepatocytes. The circulating pool
of iron bound to transferrin is determined by the activities of
these cells. These can be further categorized as epithelial cells
that transfer iron across their apical and basolateral mem-
branes (preplacental and placental cells, enterocytes), cells
that store and release iron as needed (macrophages and hepa-
tocytes), and cells that utilize iron but do not release it before
they senesce (erythroid precursors).
Iron cannot pass through cellular membranes unassisted. To
date, two transmembrane transporters have been identified—
SLC11A2 (also known as DMT1, Nramp2, and DCT1) and fer-
roportin (also known as SLC40A1, IREG1, and MTP1) (Abboud
and Haile, 2000; Donovan et al., 2000; Fleming et al., 1997;
Gunshin et al., 1997; McKie et al., 2000). SLC11A2 acts as an
iron importer, transporting iron into cells. Ferroportin acts as
an iron exporter, transporting iron out of cells. Accordingly, in
polarized epithelial cells, SLC11A2 is found on the apical
membrane, and ferroportin is found on the basolateral mem-
brane (Canonne-Hergaux et al., 1999; Donovan et al., 2000).
SLC11A2 is also found in endosomes in erythroid precursors
(Canonne-Hergaux et al., 2001; Fleming et al., 1998; Su et al.,
1998), which use the transferrin cycle for iron uptake. Ferropor-
tin is not expressed in erythroid cells but is present in the pla-
centa, intestine, reticuloendothelial macrophages, and hepato-VIER INC. DOI 10.1016/j.cmet.2005.01.003 191
A R T I C L Ecytes (Abboud and Haile, 2000; Donovan et al., 2000; McKie
et al., 2000).
Studies of animals carrying loss-of-function mutations in
Slc11a2 suggested that it was the major if not the only trans-
membrane importer of nonheme iron (Fleming et al., 1997,
1998). In contrast, evidence for a major role for ferroportin in
mammalian iron export has been indirect. Zebrafish embryos
carrying mutations in a ferroportin ortholog have a defect in
iron transfer from yolk sac to embryo (Donovan et al., 2000).
Ferroportin has been shown to have iron export function when
expressed in Xenopus oocytes (Donovan et al., 2000; McKie et
al., 2000). The ferroportin mRNA contains an iron regulatory
element in its 5# untranslated region (Abboud and Haile, 2000;
Donovan et al., 2000; Liu et al., 2002; McKie et al., 2000). Reg-
ulation of gene expression in intestine and macrophages is
consistent with expectations for a major iron exporter (Knutson
et al., 2003; McKie et al., 2000; Muckenthaler et al., 2003). In
addition, perturbation of the ferroportin promoter region in
mice causes transitory polycythemia (pcm/+) and iron defi-
ciency anemia (pcm/pcm) (Mok et al., 2004). These observa-
tions are all suggestive, but none directly address the roles of
ferroportin in normal iron homeostasis.
Formally, it was possible that hemochromatosis could result
from aberrant regulation of iron import, iron export, or both. An
important clue came from the discovery of hepcidin, a circulat-
ing peptide that has profound effects on iron absorption and
distribution (Nicolas et al., 2001, 2002). Hereditary hemochro-
matosis is associated with inappropriately low hepcidin levels,
either resulting from mutations in hepcidin itself or from muta-
tions in genes that must, in some way, control hepcidin expres-
sion (Bridle et al., 2003; Kawabata et al., 2005; Muckenthaler
et al., 2003; Nemeth et al., 2005; Nicolas et al., 2003; Papani-
kolaou et al., 2004; Roetto et al., 2003).
Recently, insight into hepcidin function came from the obser-
vation that hepcidin binds to ferroportin and targets it for de-
struction. The consequent hypothesis is that hemochromatosis
results from unimpeded iron transport through ferroportin. Clin-
ical findings could be explained by a greater transfer of iron
from absorptive intestinal epithelial cells to the bloodstream
and accelerated macrophage iron release. If this is correct, fer-
roportin must be the primary conduit for iron export from both
types of cells. The experiments described in this report test
that interpretation and provide confirmation that it is correct.
The role of ferroportin in vivo has been confounded by the
finding that mutations in ferroportin occur in a subset of human
patients with iron overload. Individuals heterozygous for a vari-
ety of missense mutations in ferroportin develop macrophage-
predominant iron overload that may progress to iron-induced
organ damage (Montosi et al., 2001; Njajou et al., 2001; Piet-
rangelo, 2004). This has been referred to as autosomal domi-
nant hemochromatosis or, more accurately, “ferroportin dis-
ease” (Pietrangelo, 2004). If it is true that ferroportin plays
important roles in both enterocytes and macrophages, there is
no simple loss-of-function or gain-of-function model to explain
this disorder. Gain-of-function mutations might lead to the in-
creased intestinal iron absorption observed in patients with au-
tosomal dominant ferroportin disease but would not account
for macrophage iron loading. Loss-of-function mutations
would explain the large amount of iron observed in patient ma-
crophages but would not readily account for increased intesti-
nal iron absorption. A hypothesis has been set forth to recon-192cile this—that macrophage iron retention leads to iron-
restricted erythropoiesis, and a compensatory augmentation of
intestinal absorption overcomes haploinsufficiency of ferropor-
tin in enterocytes. In support of this hypothesis, some patients
have been reported to have anemia early in the course of
their disease.
The purposes of this study were to determine which cell
types are dependent upon ferroportin function and to directly
test the hypothesis that ferroportin disease results from hetero-
zygous loss-of-function mutations in ferroportin. We took ad-
vantage of strong similarities between murine and human iron
metabolism (Andrews, 2000). We inactivated the murine ferro-
portin gene globally and in selected tissues, through gene
targeting and homologous recombination in pluripotential em-
bryonic stem cells. Our studies show that ferroportin is re-
quired for both prenatal and postnatal iron homeostasis. Speci-
fically, we find that ferroportin is required for iron transfer in
the extraembryonic visceral endoderm and for iron export from
enterocytes, macrophages, and hepatocytes.
Results
Targeted disruption of ferroportin results
in embryonic lethality
To generate a ferroportin (Fpn) knockout allele, we replaced
exon 6 and part of exon 7 (amino acids 172–338) with a neo-
mycin resistance cassette using homologous recombination in
J1 embryonic stem (ES) cells (see Figure S1A with the Supple-
mental Data available with this article online). This knockout
strategy deletes sequence that encodes three of the ten pre-
dicted transmembrane segments of the ferroportin protein. We
identified correctly targeted clones by Southern blot analysis.
We injected targeted ES cells into blastocysts to obtain chi-
meric animals, which were bred with 129/SvEvTac females to
produce F1 offspring carrying the modified ferroportin allele.
We confirmed germline transmission of the targeted allele by
Southern blot analysis (Figure S1B). Animals carrying the
targeted allele will be referred to as Fpnnull/+ or Fpnnull/null.
We interbred Fpnnull/+ animals in an attempt to produce
Fpnnull/null offspring. However, we obtained no Fpnnull/null ani-
mals among 150 pups genotyped, indicating that Fpnnull/null
animals died prenatally (Table 1). We determined that mostTable 1. Analysis of offspring from intercrosses of Fpn1null/+ animals
Age Fpn+/+ Fpnnull/+ Fpnnull/null Resorbed Total
E7.5 5 7 1 3 16
E8.5 2 4 1 5 12
E9.5 7 9 0 6 22
>E10.5 10 21 0 9 40
Total 24 41 2 23 90
% 26.7 45.6 2.2 25.6
Postnatal 65 85 0 150
We sacrificed and dissected pregnant mothers at different times postfertilization.
At each time point, we counted the total number of embryonic sacs present in
the uterus. Subsequently, each sac was dissected to reveal the embryo. Sacs
that were empty were categorized as resorbed. Each embryo was developmentally
staged according to Theiler (1989). The total numbers of embryos of each
genotype (Fpn+/+, Fpnnull/+, and Fpnnull/null) and the total number of resorbed
embryos were counted for each developmental stage. The genotypes of animals
from live births are summarized at the bottom of the table.CELL METABOLISM : MARCH 2005
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tify one Fpnnull/null embryo at E7.5 and one at E8.5 (Table 1).
We reproduced these results in animals carrying a targeted fer-
roportin allele from which the neomycin cassette had been re-
moved (data not shown).
Role for ferroportin in extraembryonic visceral endoderm
We hypothesized that Fpnnull/null embryos died from a defect
in iron transfer from the mother. The extraembryonic visceral
endoderm (exVE) functions in maternoembryonic nutrient
transport prior to placenta formation (Bielinska et al., 1999).
We examined the expression of ferroportin in early embryos by
immunohistochemistry. In wild-type embryos, ferroportin was
strongly expressed at the basolateral membrane of polarized
epithelial cells in the exVE (Figure 1A). Analogous studies of
littermates from intercrosses of Fpnnull/+ animals identified em-
bryos with no ferroportin expression in the exVE (Figure 1B).
These animals were significantly smaller than their ferroportin-
expressing littermates and were presumed to be Fpnnull/null em-
bryos. Considering the known function of ferroportin in cellular
iron export, it appears that Fpnnull/null embryos cannot transfer
iron from the exVE into the embryo proper, leading to a defect
in embryonic growth and consequent death.
Fpnnull/+ animals have a mild disruption
of iron homeostasis
Although Fpnnull/null animals died early in development,
Fpnnull/+ animals were viable. If simple loss-of-function muta-
tions in ferroportin cause autosomal dominant iron overload in
the human disease, then Fpnnull/+ mice should be a model of
that disorder. To test this hypothesis, we analyzed parameters
of iron homeostasis in Fpnnull/+ animals as compared to wild-
type littermates. At age 3 months, Fpnnull/+ animals were indis-
tinguishable from controls in all measurements. However, by
age 6 months, we detected evidence of disrupted iron homeo-
stasis in Fpnnull/+ animals. Fpnnull/+ mice were not anemic, but
both reticulocytes and mature erythrocytes had decreased cel-
lular hemoglobin and decreased cell volume, indicative of iron-
restricted erythropoiesis. The erythrocyte cellular hemoglobinFigure 1. Embryonic expression of ferroportin protein
Immunohistochemical staining for ferroportin in a wild-type E7.0 embryo (A). The brown staining indicates the expression of ferroportin in the extraembryonic visceral
endoderm (arrow). At higher power ([A], inset), it is evident that these cells are a polarized epithelium with ferroportin expressed on the basolateral surface, as it is in
duodenal enterocytes of the intestine. A littermate of the embryo in (A) that appears significantly smaller and has no detectable ferroportin protein by immunohistochem-
istry (B). The arrow points to the extraembryonic visceral endoderm.CELL METABOLISM : MARCH 2005content was 15.0 ± 0.2 pg in Fpn+/+ males (n = 9) and 14.1 ±
0.2 pg in Fpnnull/+ males (n = 5). The difference was highly sig-
nificant (p value% 0.00001). The erythrocyte mean cell volume
was 51.4 ± 0.9 fL in Fpn+/+ males (n = 9) and 48.7 ± 1.4 fL in
Fpnnull/+ males (n = 5) (p value % 0.01). Six-month-old Fpnnull/+
male mice also had significantly less nonheme iron in the liver
and showed a trend toward lower spleen iron when compared
to wild-type littermates (liver: Fpnnull/+ 158.8 ± 64.9 g/g,
Fpn+/+ 243.3 ± 45.8 g/g, p value % 0.04; spleen: Fpnnull/+
1656.8 ± 411.8 g/g, Fpn+/+ 2085.3 ± 449.1 g/g, p value = 0.1).
We considered the possibility that more time was needed for
the iron-loading phenotype to develop. At age 12 months,
Fpnnull/+ mice continued to have significantly lower erythrocyte
cellular hemoglobin and mean cell volume as compared to
wild-type littermates (data not shown). In addition, liver iron
content remained lower in Fpnnull/+ mice (116.2 ± 26.8 g/g,
n = 20) than in Fpn+/+ littermates (178.3 ± 33.1 g/g, n = 14)
(p value % 0.00001). However, spleen iron content in Fpnnull/+
animals was greater (2259.24 ± 392.9 g/g, n = 20) than in
Fpn+/+ animals (1797.16 ± 289.6 g/g, n = 14) (p value %
0.0005).
Most nonheme iron in the spleen is contained in macro-
phages, while nonheme iron in the liver is contained in both
hepatocytes and macrophages. At 1 year of age, increased
splenic iron suggests that iron is being retained in macro-
phages in Fpnnull/+ animals to a greater degree than in wild-
type controls. This is similar to the human iron overload
disease due to ferroportin mutations. However, in contrast to
human patients, hepatic iron stores were diminished. Thus, our
data suggest that Fpnnull/+ mice are not a faithful model of the
human disease.
Conditional disruption of ferroportin
In order to study the role of ferroportin in adult mouse tissues,
we retargeted the ferroportin locus and introduced LoxP sites
into introns flanking exons 6 and 7 to generate a “floxed” allele
(Figure S1A). We refer to mice that are homozygous for the
floxed allele as Fpnflox/flox. In the presence of Cre recombinase,
sequences between the LoxP sites can be excised. This condi-193
A R T I C L Etional knockout strategy deletes sequence that encodes six of
the ten predicted transmembrane segments of the ferroportin
protein.
Ferroportin is required for iron homeostasis after birth
To circumvent embryonic lethality due to loss of ferroportin in
tissues involved in maternoembryonic iron transfer, we bred
Fpnflox/flox animals to Meox2-Cre mice (Tallquist and Soriano,
2000). Meox2-Cre;Fpnflox/flox mice should express Cre recom-
binase and inactivate ferroportin in all tissues except exVE and
placenta. Meox2-Cre;Fpnflox/flox mice were born alive and ini-
tially appeared identical to their wild-type littermates. However,
within the first few days of life, they were noted to be pale
and runted. By P10–P12, the difference between wild-type and
mutant animals was pronounced (Figure 2A). We observed
variability in both the onset and severity of the phenotype,
likely due to incomplete Cre-mediated excision in some ani-
mals. Accordingly, genotyping of animals with severe pheno-
types demonstrated complete or near-complete excision of the
floxed allele in all tissues and organs examined, whereas exci-
sion was incomplete in animals with milder phenotypes (data
not shown).
Meox2-cre;Fpnflox/flox mice were anemic, explaining their
pallor. Blood smears revealed hypochromia, anisocytosis, poi-
kilocytosis, and reticulocytosis (Figures 2B and 2C), similar to
other mouse mutants with severe iron deficiency anemia. Mea-
surement of erythrocyte parameters revealed decreased total
hemoglobin, mean cell volume, and mean cell hemoglobin in
both reticulocytes and mature erythrocytes (Table S1). The red
cell distribution width and reticulocyte count were increased.
These data strongly support the conclusion that the anemia in
Meox2-Cre;Fpnflox/flox mice resulted from iron deficiency.
We examined tissues suspected to require ferroportin func-
tion including duodenum, liver, and spleen. Because ferroportin
functions as an iron exporter, loss of its activity should result
in cellular iron retention, demonstrable by histochemical stains
that detect nonheme iron. We compared tissues from Meox2-
Cre;Fpnflox/flox mice and wild-type littermates. Wild-type ani-
mals had no stainable nonheme iron in duodenal enterocytes
(Figure 3A). In contrast, Meox2-Cre;Fpnflox/flox mice had abun-
dant enterocyte iron (Figure 3B), suggesting that iron taken up
from the diet or plasma cannot be exported across the basolat-
eral membrane into the circulation. Considering the substantial
requirement for efficient dietary iron absorption to support
growth in the first 3 weeks of life, this intestinal defect might,
by itself, explain the development of iron deficiency anemia in
the mutant animals.
We also examined tissue sections from the liver and spleen.
Wild-type liver samples showed no detectable iron in hepato-
cytes or Kupffer cells at age 12 days. In contrast, Meox2-
Cre;Fpnflox/flox mice showed pronounced iron accumulation in
Kupffer cells, the resident macrophages of the liver, and in he-
patocytes (Figures 3C and 3D). We also observed considerable
iron accumulation in splenic macrophages of Meox2-Cre;
Fpnflox/flox mice but not controls (Figures 3E and 3F). These
observations support the hypothesis that ferroportin is impor-
tant for export of iron from both macrophages and hepato-
cytes.
We measured nonheme tissue iron content. Meox2-Cre;Fpn
mutant animals sacrificed at 10–12 days of age had 2.3- and
1.7-fold more nonheme iron in liver and spleen, respectively,194Figure 2. Conditional deletion of ferroportin by Meox2-Cre causes iron defi-
ciency anemia
The 10-day-old Meox2-cre;Fpn1flox/flox pup ([A], bottom) is small and pale com-
pared to a wild-type littermate ([A], top). Peripheral blood smear of a 12-day-old
wild-type animal stained with Wright-Giemsa (B). Peripheral blood smear of a
12-day-old Meox2-Cre;Fpn1flox/flox animal stained with Wright-Giemsa (C).as compared to their wild-type littermates (Figure 4), consistent
with the histochemical staining. At 18–22 days of age, Meox2-
Cre;Fpn mutant animals continued to have higher spleen iron
(4.4-fold), but their liver iron content was 1.7-fold lower than
their wild-type littermates (Figure 4). This pattern is most likely
explained by the overall iron deficiency of these animals. TheCELL METABOLISM : MARCH 2005
Ferroportin is essential for iron homeostasisFigure 3. Meox2-Cre;Fpn mutant mice accumulate
iron in enterocytes, macrophages, and hepatocytes
Perls Prussian blue stain for iron in crosssections of
duodenal villi of 12-day-old mice (A and B). Blue
staining shows iron accumulated in enterocytes.
DAB-enhanced Perls stain for iron in liver sections
from 12-day-old mice (C and D). Brown staining
shows iron accumulated in cells. The asterix (*)
marks a Kupffer cell, and the arrow points to hepa-
tocytes that are loaded with iron. DAB-enhanced
Perls stain for iron in spleen sections of 12-day-old
mice (E and F). The genotypes of the mice are the
following: Fpnflox/flox (A, C, and E) and Meox2-Cre;
Fpnflox/flox (B, D, and F).liver continues to grow in size with increasing age, but iron-
deficient animals cannot deposit additional iron in hepatocytes,
eventually leading to a decrease in liver iron content.
Ferroportin is important in intestinal iron absorption
We wanted to develop mice expressing ferroportin in all tissues
except the intestine in order to distinguish the role of the pro-
tein in the intestine from its roles in other cell types. Initially, we
bred Fpnflox/flox animals to mice expressing Cre recombinase
under the control of the villin promoter (el Marjou et al., 2004).
In adult animals, villin expression is highly restricted to the in-
testine and, to a lesser extent, the kidney. However, similar to
our first, global knockout model, no ferroportin-deleted mice
were born. Because intestinal ferroportin should not be re-
quired before birth, we suspected that the villin-Cre transgene
was also expressed in the exVE, resulting in early deletion of
ferroportin and embryonic death. Subsequent studies con-
firmed that the villin promoter directs expression of Cre recom-
binase in exVE (el Marjou et al., 2004).
To bypass this problem, we bred Fpnflox/flox mice to miceCELL METABOLISM : MARCH 2005carrying an intestine-restricted villin-Cre transgene that is in-
ducible by tamoxifen (el Marjou et al., 2004). The resulting vil-
Cre-ERT2;Fpnflox/flox mice should be born with ferroportin al-
leles intact. However, after administration of tamoxifen, Cre
recombinase causes tissue-specific inactivation of ferroportin.
We administered tamoxifen to vil-Cre-ERT2;Fpnflox/flox and
Fpnflox/flox mice starting at age 1 week. We confirmed by both
PCR and Southern blot analyses that inactivation of ferroportin
occurred exclusively in the intestine (Figure 5A and data not
shown). Approximately 50% of the total DNA in a duodenal
segment showed ferroportin deletion. Based on earlier charac-
terization of the vil-Cre-ERT2 mouse model, it is likely that the
observed 50% deletion in whole intestine corresponds to
100% deletion in crypt cells and enterocytes, with no deletion
in nonepithelial cell types (el Marjou et al., 2004). In order to
confirm that ferroportin was not expressed in vil-Cre-ERT2;
Fpnflox/flox mice, we performed immunohistochemistry with an
anti-ferroportin antibody. Ferroportin is clearly expressed on
the basolateral surface of enterocytes in the duodenum of
Fpnflox/flox mice, but is absent in vil-Cre-ERT2;Fpnflox/flox mice
(Figures 5B and 5C).195
A R T I C L EFigure 4. Meox2-Cre;Fpn mutant mice have abnor-
mal nonheme iron levels in liver and spleen
Box plot depicting the measurement of nonheme
iron levels (g Fe/g wet weight) in liver and spleen
of wild-type controls (pink boxes) and Meox2-Cre;
Fpn mutants (white boxes). The genotypes of the
Meox2-Cre;Fpn mutant mice were Meox2-Cre;
Fpnflox/flox and Meox2-Cre;Fpnflox/null. The genotypes
of the wild-type controls were Fpnflox/flox, Fpnflox/+,
and Fpnflox/null. We analyzed animals at two different
ages: (1) 10- to 12-day-old mice (wild-type n = 6
and mutant n = 7) and (2) 18- to 22-day-old mice
(wild-type n = 13 and mutant n = 11). This data was
collected from both male and female animals. p val-
ues were calculated using Student’s T-test. The box
plot was drawn using Statview 5.0.1 (SAS Institute,
Inc.) The middle bar of the box represents the me-
dian. The top of the box is the 75th percentile of
the data set, and the bottom of the box is the 25th
percentile. The top whisker represents the 90th per-
centile of the data, and the bottom whisker repre-
sents the 10th percentile of the data. The circles re-
present data points that lie outside of the 10th and
90th percentiles.The vil-Cre-ERT2;Fpnflox/flox mice were visibly anemic as early
as 8 days after the first tamoxifen injection. At 6–7 weeks of
age, peripheral blood smears were consistent with severe iron
deficiency anemia (Figures 6A and 6B). The average hematocrit
of vil-Cre-ERT2;Fpnflox/flox animals was 11.2% ± 1.6% (n = 9),
compared to 45.3% ± 5.9% (n = 11) in Fpnflox/flox controls (p
value % 0.00001). The average hemoglobin concentration of
mutant mice was 2.8 ± 0.6 g/dl (n = 9), compared to 13.8 ± 1.8
g/dl (n = 11) in wild-type littermates (p value % 0.00001). The
duodenal enterocytes of vil-Cre-ERT2;Fpnflox/flox animals
showed marked iron accumulation (Figures 6C and 6D). How-
ever, there was no stainable iron in the liver or spleen of vil-
Cre-ERT2;Fpnflox/flox animals (data not shown). The vil-Cre-
ERT2;Fpnflox/flox mice had 4.7-fold less nonheme iron in liver
and 5.5-fold less nonheme iron in spleen as compared to their
Fpnflox/flox littermates (liver: vil-Cre-ERT2;Fpnflox/flox 23.0 ± 3.9
g/g, Fpnflox/flox 106.9 ± 6.3 g/g, p value % 0.0003; spleen:
vil-Cre-ERT2;Fpnflox/flox 27.0 ± 5.8 g/g, Fpnflox/flox 148.3 ± 25.9
g/g, p value % 0.013). This severe iron deficiency is consis-
tent with an important role for ferroportin in intestinal iron ab-
sorption. When ferroportin is inactivated exclusively in the in-
testine but intact in other tissues, iron is not retained in
macrophages and hepatocytes, consistent with an appropriate
response to iron deficiency.
If anemia and iron deficiency in vil-Cre-ERT2;Fpnflox/flox ani-
mals result from a block in intestinal iron absorption, it should
be possible to restore normal iron balance through parenteral
treatment with iron dextran. Accordingly, after administration
of iron dextran, the hematocrits of vil-Cre-ERT2;Fpnflox/flox
mice returned to normal within 1 week. The hematocrits of
Fpnflox/flox animals before and after treatment ranged from 46%
to 49%. Before treatment, the hematocrits of vil-Cre-ERT2;
Fpnflox/flox animals ranged from 9% to 11%. One week later,
untreated vil-Cre-ERT2;Fpnflox/flox mice still had a mean hema-
tocrit of 8.9% ± 2.2% (n = 3), while the iron dextran-treated vil-196Cre-ERT2;Fpnflox/flox mice had a mean hematocrit of 41.7% ±
4.5% (n = 3) (p value% 0.002). These results confirm that ferro-
portin is critical for intestinal absorption of iron.
Discussion
Our findings indicate that ferroportin is the major (if not only)
basolateral iron exporter functioning in epithelial cells of the
exVE and the intestine. When ferroportin is inactivated globally,
there is an early failure in embryonic development, likely due
to iron insufficiency. When it is preserved in the exVE and pla-
centa but inactivated in all other tissues, prenatal development
proceeds normally, but iron deficiency ensues rapidly after
birth, when the intestine becomes the only route for iron entry.
Selective inactivation of ferroportin in postnatal intestine re-
sulted in severe iron deficiency that was corrected by paren-
teral administration of iron, confirming that ferroportin function
is necessary for dietary iron absorption in mice. While it re-
mains possible that there are alternative, minor pathways for
enterocyte iron export, the severity of the phenotype suggests
that none can substitute for the activity of ferroportin.
The requirement for ferroportin activity in the intestine has
additional implications for iron homeostasis. The undifferenti-
ated crypt cells that develop into enterocytes, and perhaps the
enterocytes themselves, acquire iron from the circulation (Be-
dard et al., 1976). The amount of plasma iron entering these
cells is not insignificant, because the surface area of the villous
epithelium is immense. If export of iron is interrupted, the flow
of iron into this compartment becomes unidirectional. Entero-
cytes have a limited lifespan—after several days, they senesce
and are sloughed into the gut lumen, resulting in loss of any
iron they contain. Thus, we would expect that animals lacking
intestinal ferroportin function would not only have a defect in
iron absorption—they would also have increased iron losses.
While it has been assumed that there is no regulated ironCELL METABOLISM : MARCH 2005
Ferroportin is essential for iron homeostasisFigure 5. Conditional deletion of ferroportin in enterocytes by vil-Cre-ERT2
PCR analysis of tissue DNA from a vil-Cre-ERT2;Fpnflox/flox mouse that was in-
jected with tamoxifen (A). Tail (T), liver (L), spleen (S), kidney (K), lung (Lu), pan-
creas (P), heart (H), intestine (I). The marker is a 100 bp ladder. The floxed allele
is 522 bp, and the full deletion allele is 398 bp. Immunohistochemistry for ferro-
portin protein in a wild-type animal (B) and a vil-Cre-ERT2;Fpnflox/flox mouse in-
jected with tamoxifen (C). Brown staining represents ferroportin expression in
duodenal enterocytes. Higher magnification images show basolateral localization
of ferroportin in the wild-type animals ([B], inset) and absence of ferroportin ex-
pression in the vil-Cre-ERT2;Fpnflox/flox mouse ([C], inset).CELL METABOLISM : MARCH 2005excretion because neither the liver nor the kidney efficiently
releases iron from the body, our results suggest that iron loss
could be regulated at a different level. In iron deficiency, in-
creased ferroportin expression would not only ensure in-
creased intestinal absorption but also allow for maximal recov-
ery of iron that has entered the intestinal epithelium from the
plasma. On the other hand, decreased ferroportin expression
in iron overload could augment normal iron losses by increas-
ing the amount of iron contained in exfoliated enterocytes.
Thus, regulation of ferroportin might be considered a novel
mechanism of regulating iron “excretion.” This need not occur
through a mechanism that regulates the production of ferropor-
tin. Indeed, hepcidin can exert control of ferroportin by modu-
lating protein levels (Nemeth et al., 2004). This homeostatic
mechanism allows regulation of intestinal iron absorption in re-
sponse to iron availability and needs elsewhere in the body.
We have shown that ferroportin also plays important roles in
nonepithelial cells. Global inactivation of ferroportin resulted in
other perturbations of cellular iron distribution. Macrophages
of the liver and spleen showed marked iron retention, likely
because they had phagocytosed effete erythrocytes but had
no mechanism for releasing recovered iron. Hepatocytes also
appeared to retain the iron that they had acquired prenatally.
These observations suggest that, as in enterocytes, ferropor-
tin is the major iron exporter functioning in iron-recycling
macrophages and hepatocytes. Iron retention by those cells
undoubtedly compounds the effects of inadequate iron ab-
sorption, further depriving erythroid precursors of iron for he-
moglobin production and thus exacerbating the anemia.
Few other cell types need to have an iron export function.
However, iron transfer across the blood-brain barrier does re-
quire a cellular export step. We have not directly addressed the
role of ferroportin in the brain in this study. However, in a sepa-
rate study, we bred with mice expressing Cre recombinase un-
der the control of a nestin promoter (Tronche et al., 1999) and
did not note any gross behavioral abnormalities that might be
attributed to cerebral or cerebellar dysfunction (data not
shown).
Mice heterozygous for ferroportin mutations have a subtle
phenotype that is not measurable before 6 months of age. Sim-
ilar to human patients with autosomal dominant ferroportin dis-
ease, they accumulated iron in tissue macrophages and
showed mild evidence of iron-restricted erythropoiesis. How-
ever, even at 1 year of age, they did not appear to have in-
creased liver iron that would have been indicative of total body
iron overload.
There are several possible explanations for the differences
between Fpnnull/+ mice and human patients. First, it might be
that clinical iron overload requires more time, and 1 year is not
long enough for it to become manifest. This seems unlikely,
because liver iron content was consistently decreased in
Fpnnull/+ mice. Alternatively, it might be that mice and humans
respond differently to heterozygous loss-of-function of this
gene. We favor a third hypothesis—that human ferroportin mu-
tations are not simple loss-of-function mutations and therefore
not directly analogous to the situation in Fpnnull/+ mice. Muta-
tions may not affect iron transport, per se, but rather perturb
critical protein-protein interactions that might be cell type spe-
cific. Accordingly, it is interesting to note that no frameshift or
termination codon mutations have been found among the
many patients analyzed to date.197
A R T I C L EFigure 6. Ferroportin is critical for intestinal iron ab-
sorption
Wright-Giemsa-stained peripheral blood smears of
tamoxifen-injected Fpnflox/flox (A) and vil-Cre-ERT2;
Fpnflox/flox (B) animals. Perls stain for nonheme iron
in the duodenum of tamoxifen injected Fpnflox/flox (C)
and vil-Cre-ERT2;Fpnflox/flox (D) animals. Blue stain-
ing represents nonheme iron accumulation in duo-
denal enterocytes.These studies also explain why hepcidin deficiency results
in clinical hemochromatosis. Hepcidin acts as a modulator of
ferroportin function by triggering its degradation (Nemeth et al.,
2004). Normally, increased iron availability stimulates hepcidin
expression, probably triggering a homeostatic response in
which hepcidin binds to ferroportin to cause its degradation.
We can conclude that this is effective in controlling iron homeo-
stasis because we have shown that ferroportin gates iron re-
lease at two key sites—in absorptive intestinal epithelial cells
and recycling macrophages. We propose that, in hemochro-
matosis, perturbations in iron homeostasis result from a failure
to control iron export through ferroportin, leading to increased
iron release from macrophages and enhanced intestinal ab-
sorption.
Experimental Procedures
Targeted mutagenesis of ferroportin
Both the global and conditional targeting constructs modified a 15.5 kb
KpnI fragment containing exons 4–8 of the mouse ferroportin genomic lo-
cus (Figure S1A). We used the pTKLNCL vector (originally from R. Morten-
son). For the traditional targeting construct, the XhoI/BamHI fragment con-
taining exon 6 and part of exon 7 was replaced by a 4.5 kb LoxP flanked
cassette encoding a neomycin resistance gene and a cytosine deaminase
gene. For the conditional targeting construct, the LoxP flanked cassette
was inserted into an XhoI site in intron 5. A third LoxP site was inserted into
an SphI site in intron 7 (Figure S1A). Coding sequence for thymidine kinase
was also present in the pTKLNCL vector outside of the homology regions.
The targeting constructs were introduced by electroporation into J1 embry-
onic stem cells (129 background), and cells were selected for resistance to
G418 and ganciclovir. DNA samples from clones resistant to both G418 and
ganciclovir were examined for homologous recombination by Southern blot
analysis of HindIII digested DNA using a probe to exon 3 (Figures S1B and
S1C). For each targeted allele (total knockout and conditional knockout), a
single homologously recombined clone with a normal karyotype was in-
jected into C57BL/6J mouse blastocysts, and these were transferred into
the uteri of pseudopregnant females. High percentage male chimeras were198bred with 129/SvEvTac females to generate F1 offspring carrying the modi-
fied ferroportin alleles. Germline transmission of the modified ferroportin
alleles was determined by Southern blot analysis of tail DNA samples. For
the conditional knockout model, we removed the neomycin resistance cas-
sette from the targeted allele by mating to transgenic mice expressing Cre
recombinase under control of the E2A promoter (Lakso et al., 1996). The
E2A-Cre transgenic line had a 129/SvEvTac background.
Animals
Mice were maintained on standard mouse diet. Both the Fpn null and Fpn-
floxed lines were maintained on the 129/SvEvTac background. For timed
matings of Fpnnull/+ animals, the morning a plug was identified was consid-
ered E0.5. Plugged females were then sacrificed at E6.5 and later. Embryos
were dissected from the uterus and either genotyped or used for immuno-
histochemistry. The Meox2-Cre mouse strain was obtained from the Jack-
son Laboratory (Bar Harbor, ME) on a mixed B6.129S4 background
(Tallquist and Soriano, 2000). The vil-Cre-ERT2 transgenic line was obtained
on a mixed background of B6/D2 and BL6 (el Marjou et al., 2004). The
Meox2-Cre and vil-Cre-ERT2 mice were mated to Fpnflox/+ animals to create
Meox2-Cre; Fpnflox/+ and vil-Cre-ERT2; Fpnflox/+ mice. SinceMeox2-Cre can
cause deletion in the germline, we also obtained Meox2-Cre;Fpnnull/+ mice
from these crosses. Mice with the three genotypes described above were
subsequently mated to Fpnflox/flox animals to create the animals that were
studied in these experiments. Administration of tamoxifen to Fpnflox/flox and
vil-Cre-ERT2; Fpnflox/flox mice was performed once daily for 4 days starting
between 7 and 10 days after birth. Tamoxifen (Sigma, St. Louis, MO) was
first dissolved in 100% ethanol (50 mg/ml). Injection solution was prepared
by diluting the tamoxifen to 8.3 mg/ml in sunflower seed oil (Sigma). Mice
were weighed and injected with an amount of tamoxifen equal to 0.075
mg/g mouse. Mice were injected subcutaneously into the subscapular re-
gion with a single dose of either 1 mg or 5 mg of Fe-dextran (Watson
Pharma, Morristown, NJ).
Southern blot and PCR genotyping
For Southern blot analysis, 10 g of genomic DNA (Puregene Kit, Gentra
Systems, Minneapolis, MN) was digested overnight with either HindIII or
BamHI restriction enzyme, fractionated on a 0.5% TAE agarose gel, and
transferred to Hybond N+ membrane (Amersham Biosciences, Piscataway,
NJ). The probe for Southern blots was labeled by incorporation of 32P-dCTPCELL METABOLISM : MARCH 2005
Ferroportin is essential for iron homeostasisinto a PCR product amplified with the following primers: forward
5#-GCAATTTATTGGGTATAGCAG-3# and reverse 5#-TGCCACCACCAGTCC
ATAGAC-3#. We genotyped mice by PCR analysis. Fpnnull/+ mice and em-
bryos from intercrosses were genotyped using two PCR reactions. The
wild-type allele (355 bp) was identified by amplification with the forward
primer 5#-CTACACGTGCTCTCTTGAGAT-3# (Xho5#) and the reverse primer
5#-GGTTAAACTGCTTCAAAGG-3# (Xho3#). The targeted allele (359 bp) was
identified by amplification with the same forward primer (Xho5#) and a re-
verse primer, 5#-GCCAAGTTCTAATTCCATCAG-3#, derived from the
targeting vector. The Fpnflox/+ and Fpnflox/flox mice were genotyped with one
PCR reaction that had one forward primer (Xho5#) and two reverse primers,
Xho3# and 5#-CCTCATATGTGAGTCAAAGTATAG-3#. The wild-type allele
generated a 355 bp band, and the floxed allele generated a 522 bp band.
The band generated by full deletion with Cre recombinase was 398 bp. The
Meox2-Cre mice were genotyped with primers that amplify Cre recombi-
nase (200 bp): CREF (5#-CGTATAGCCGAAATTGCCAG-3#) and Cre-2-1
(5#-CAAAACAGGTAGTTATTCGG-3#). The vil-Cre-ERT2 mice were geno-
typed with the primers villin Cre-F (5#-CAAGCCTGGCTCGACGGCC-3#)
and villin Cre-R (5#-CGCGAACATCTTCAGGTTCT-3#), resulting in a 300 bp
band.
Immunohistochemistry
Immunohistochemistry of embryos was performed with a rabbit polyclonal
anti-mouse ferroportin antibody elicited by injecting a fusion protein of glu-
tathione S-transferase and 80 amino acids (residues 224–304) of mouse
ferroportin protein into a New Zealand White rabbit. Antiserum was affinity
purified against the same ferroportin peptide segment fused to dihydrofo-
late reductase using a preparative immunoblot procedure, as previously de-
scribed (Canonne-Hergaux et al., 1999). Specificity to mouse ferroportin
was confirmed by Western blot on membrane preparations from Madin-
Darby canine kidney (MDCK) cells stably expressing ferroportin carrying a
single missense mutation fused to green fluorescent protein at the C termi-
nus (data not shown; F. Canonne-Hergaux, submitted). Embryos in their
deciduum were fixed in 10% buffered formalin (Fisher Scientific, Fair Lawn,
NJ) and embedded in paraffin. Sections were deparaffinized and heat
treated for 30 min in 1.0 mM EDTA (pH 8.0) in an HS80 steamer (Black and
Decker). Endogenous peroxidase activity was quenched with 3% aqueous
hydrogen peroxide. Slides were then incubated in 3% normal swine serum
in 0.05 M Tris (pH 7.6) followed by rabbit anti-ferroportin antibody (1:200
dilution) for 16 hr at room temperature. Slides were then incubated for 40
min with a horseradish peroxidase-labeled polymer conjugated to goat anti-
rabbit immunoglobulin (EnVision+, Dako, Carpinteria, CA). Following anti-
body localization with 3.3#-diaminobenzidine tetrahydrochloride (DAB+,
Dako), the stain was intensified by using a DAB enhancing solution (Zymed,
South San Francisco, CA). Slides were counterstained with methyl green,
dehydrated, and covered in Polymount (Poly Scientific, Bay Shore, NY).
Immunohistochemistry on intestine sections was performed with a pre-
viously described polyclonal antibody against the C terminus of ferroportin
(Donovan et al., 2000). The same procedure described above was followed,
except that the antibody was incubated at a 1:400 dilution and for 1 hr.
Tissue iron staining and quantitative tissue iron measurements
Intestine, liver, and spleen samples were fixed in 10% buffered formalin and
embedded in paraffin. Deparaffinized tissue sections were stained with the
Perls Prussian blue stain for nonheme iron in the Children’s Hospital Boston
Pathology Laboratory. A subset of tissue sections was stained with a DAB-
enhanced Perls iron stain (Dragatsis et al., 1998). Deparaffinized tissue sec-
tions were incubated for 30 min in 1% potassium ferrocyanide in 0.12N
HCl. Endogenous peroxidase activity was quenched for 20 min at room
temperature in 0.3% H2O2 in methanol. Sections were rinsed in PBS and
incubated for 6 min in DAB/ H2O2 (DAB Plus Substrate Kit, Zymed). Quanti-
tative measurement of nonheme iron was performed as described (Levy et
al., 1999). Data is expressed as g Fe/g wet weight of tissue.
Blood cell analysis
Mice were bled retroorbitally under anesthesia with 125–240 g/kg avertin
(Sigma). Blood smears were stained with Wright-Giemsa stain (Fisher Diag-
nostics, Middletown, VA). Blood for complete blood counts was collected
into 600 l EDTA anticoagulated microtainer tubes (Becton Dickenson,
Franklin Lakes, NJ) and analyzed on an ADVIA 120 hematology analyzerCELL METABOLISM : MARCH 2005(Bayer, Tarrytown, NY) with software specialized for mouse blood. Blood
analysis was performed in the Clinical Core Laboratories at Children’s Hos-
pital Boston.
Statistics
We calculated all p values using Student’s t test in Microsoft Excel.
Supplemental data
Supplemental Data include one figure and one table and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/1/3/191/
DC1/.
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